Mackenzie Financial
OCUL icon

Mackenzie Financial’s Ocular Therapeutix OCUL Stock Holding History

Mackenzie Financial’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,903
Closed -$133K – 1653
2025
Q4 		$133K Buy
10,903
+746
+7% +$9.06K ﹤0.01% 1578
2025
Q3 		$119K Hold
10,157
– – ﹤0.01% 1616
2025
Q2 		$94.3K Buy
+10,157
New +$79.5K ﹤0.01% 1620
2023
Q3 		– Sell
-44,173
Closed -$221K – 1554
2023
Q2 		$221K Sell
44,173
-21,800
-33% -$130K ﹤0.01% 1300
2023
Q1 		$348K Buy
+65,973
New +$313K ﹤0.01% 1135

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Mackenzie Financial's OCUL Position: Q1 2026 in Review

Mackenzie Financial sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 10,903 shares — an estimated $133K sold.

Mackenzie Financial first reported a position in OCUL in Q1 2023 and held it in 5 quarters. The position peaked at $348K in Q1 2023. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Mackenzie Financial reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 10,903 Ocular Therapeutix shares in Q1 2026, an estimated $133K.
  • Mackenzie Financial first reported a position in Ocular Therapeutix in Q1 2023 and held it in 5 quarters.
  • Mackenzie Financial's Ocular Therapeutix position peaked at $348K in Q1 2023.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.